This Article Full Text Full Text (PDF) All Versions of this Article: 43/6/1202    most recent 01.HYP.0000127924.67353.86v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Mokwe, E. Articles by Flack, J. M. Search for Related Content PubMed PubMed Citation Articles by Mokwe, E. Articles by Flack, J. M. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information High Blood Pressure Hazardous Substances DB QUINAPRIL HYDROCHLORIDE Related Collections Clinical Studies Epidemiology

(Hypertension. 2004;43:1202.)
© 2004 American Heart Association, Inc.

Scientific Contributions

Determinants of Blood Pressure Response to Quinapril in Black and White Hypertensive Patients

The Quinapril Titration Interval Management Evaluation Trial

Evan Mokwe; Suzanne E. Ohmit; Samar A. Nasser; Tariq Shafi; Elijah Saunders; Errol Crook; Amanda Dudley; John M. Flack

From the Department of Internal Medicine (E.M.), Department of Internal Medicine, Division of Endocrinology, Metabolism, and Hypertension (S.E.O., S.A.N., J.M.F.), Department of Internal Medicine, Academic Hospitalist Program (T.S.), Department of Internal Medicine, Division of Nephrology (E.C.), and Department of Internal Medicine, Cardiovascular Epidemiology and Clinical Applications (A.D.), Wayne State University, Detroit, Mich; Department of Medicine (E.S.), University of Maryland School of Medicine, Baltimore, Md.

Correspondence to Dr John M. Flack, Department of Internal Medicine, Wayne State University, 4201 St. Antoine, 2E-UHC, Detroit, MI 48201. E-mail jflack{at}intmed.wayne.edu

Race has been considered an important factor in determining blood pressure response to treatment and selection of antihypertensive drug therapy. Data collected during a clinical trial that evaluated rapidity of medication up-titration with blood pressure response to monotherapy with the angiotensin-converting enzyme (ACE) inhibitor quinapril were used to characterize response in 533 black and 2046 white participants. Our objectives were to examine the influence of race and other factors on blood pressure response and to assess the degree to which nonrace factors account for apparent racial differences in response. Average systolic and diastolic blood pressure responses (baseline minus follow-up) to treatment were assessed with treatment groups combined. Crude systolic and diastolic blood pressure responses averaged 4.7 and 2.4 mm Hg less, respectively, in black compared with white participants; however, the response distributions largely overlapped. In multivariate linear regression models adjusted for study design variables and measured participant characteristics, the racial difference in systolic response was reduced by 51% to 2.3 mm Hg, and diastolic response by 21% to 1.9 mm Hg. In these models, participant characteristics, including age, gender, body size, and pretreatment blood pressure severity, significantly predicted either attenuated or enhanced blood pressure response to treatment. Our findings demonstrate that a large source of variability of blood pressure response to treatment is within, not between, racial groups, and that factors that vary at the level of the individual contribute to apparent racial differences in response to treatment.

Key Words: ACE inhibitors • antihypertensive therapy • blood pressure response • hypertension • race